TerminatedPhase 3NCT00761280
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Isarna Therapeutics GmbH
- Principal Investigator
- Rolando Del Maestro, MD, PhDMontreal Neurological Institute and Hospital
- Intervention
- trabedersen(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2008 – 2012
Study locations (30)
- NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
- Winthrop University Hospital, Mineola, New York, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Hospital Británico, Buenos Aires, Argentina
- FLENI, Buenos Aires, Argentina
- Sanatorio Allende, Córdoba, Argentina
- Universitätsklinik Innsbruck, Abteilung für Neurologie, Innsbruck, Austria
- AKH Wien, Klinik für Neurochirurgie, Vienna, Austria
- Hospital de Câncer de Barretos, Barretos / SP, Brazil
- Centro Goiano de Oncologia (CGO), Goiânia, Brazil
- Hospital Sao Vicente de Paulo, Passo Fundo, Brazil
- Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil
- Hospital do Servidor Público Estadual, São Paulo, Brazil
- ECOGENE-21 Centre d'études cliniques, Chicoutimi, Quebec, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00761280 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah